Wealth Enhancement Advisory Services LLC Lowers Position in Novo Nordisk A/S (NYSE:NVO)

Wealth Enhancement Advisory Services LLC lowered its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 3.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 280,813 shares of the company's stock after selling 8,625 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Novo Nordisk A/S were worth $24,156,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in NVO. NorthCrest Asset Manangement LLC increased its position in Novo Nordisk A/S by 4.4% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 11,663 shares of the company's stock valued at $1,003,000 after buying an additional 495 shares in the last quarter. Lighthouse Financial LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $1,811,000. Aegis Wealth Management LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $479,000. BridgePort Financial Solutions LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $540,000. Finally, Park Square Financial Group LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $29,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded up $1.94 on Friday, reaching $71.40. The stock had a trading volume of 11,185,051 shares, compared to its average volume of 6,787,412. The stock has a market cap of $320.41 billion, a P/E ratio of 21.70, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a 50 day simple moving average of $65.58 and a 200 day simple moving average of $81.77.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.